ArticleCureus2024
Evaluating the Feasibility and Cost-Effectiveness of EzeCheck for Hemoglobin Screening Across India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Feasibility of a Noncontact Photoplethysmography-Based Mobile App for Noninvasive Hemoglobin Monitoring: Exploratory Observational Study.JMIR formative research · 2026Observational
- Enhancing anemia diagnostics and accessibility in India: a policy recommendation for effective anemia management.Frontiers in health services · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Anemia, particularly due to low hemoglobin levels, is a significant public health concern in India. Traditional invasive screening methods can be burdensome and may limit access to diagnosis. This study evaluated the feasibility and cost-effectiveness of a noninvasive hemoglobin screening device called EzeCheck for determining hemoglobin levels across diverse populations in India. We aimed to assess the user feasibility of the EzeCheck device and to conduct a comparative analysis of its cost-effectiveness against other available invasive and noninvasive methods to determine hemoglobin levels. Methods This study adopted a mixed-methods approach, incorporating both quantitative and qualitative data for analysis. User feedback was collected through surveys and interviews with healthcare professionals and workers across various regions. A cost-effectiveness analysis compared the EzeCheck device with other available noninvasive devices and standard invasive methods, accounting for factors such as equipment costs, consumables requirements, time efficiency, and overall testing costs. Results Preliminary findings suggest that the EzeCheck device was well-received by users, with 198 (86%) healthcare professionals reporting improved workflow and patient satisfaction. The comparative analysis revealed that the EzeCheck device was the most affordable option in terms of overall screening costs, while also increasing screening efficiency to a great extent. Moreover, it provided a safer and more comfortable experience for patients and users. Conclusions The noninvasive EzeCheck hemoglobin screening device demonstrates superior feasibility and cost-effectiveness over traditional methods. This study highlights its potential for enhancing anemia detection in India, particularly in underserved areas. By improving accessibility and reducing costs, this device could significantly impact public health outcomes and inform future health policy initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.